K
Kris V. Kowdley
Researcher at Virginia Mason Medical Center
Publications - 555
Citations - 42081
Kris V. Kowdley is an academic researcher from Virginia Mason Medical Center. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Liver disease. The author has an hindex of 92, co-authored 492 publications receiving 36471 citations. Previous affiliations of Kris V. Kowdley include Benaroya Research Institute & University of Washington.
Papers
More filters
Journal ArticleDOI
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.
Journal ArticleDOI
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Kris V. Kowdley,Stuart C. Gordon,K. Rajender Reddy,Lorenzo Rossaro,David E. Bernstein,Eric Lawitz,Mitchell L. Shiffman,Eugene R. Schiff,Reem Ghalib,Michael J. Ryan,Vinod K. Rustgi,Mario Chojkier,Robert Herring,Adrian M. Di Bisceglie,Paul J. Pockros,G. Mani Subramanian,Di An,Evguenia S. Svarovskaia,Robert H. Hyland,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,David Pound,Michael W. Fried +24 more
TL;DR: Leadipasvir-sofosbuvir for 8 weeks was associated with a high rate of sustained virologic response among previously untreated patients with HCV genotype 1 infection without cirrhosis, and results indicated noninferiority of the 8-week ledipas Viral-SofosBuvir regimen.
Journal ArticleDOI
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
Ira M. Jacobson,Stuart C. Gordon,Kris V. Kowdley,Eric M. Yoshida,Maribel Rodriguez-Torres,Mark S. Sulkowski,Mitchell L. Shiffman,Eric Lawitz,Gregory T. Everson,Michael J. Bennett,Eugene R. Schiff,M. Tarek Al-Assi,G. Mani Subramanian,Di An,Ming Lin,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Keyur Patel,Jordan J. Feld,Stephen Pianko,David R. Nelson +22 more
TL;DR: In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.